

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 9/21/1980
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

Blood Culture, Acid-Fast Bacillus (AFB)

ARUP test code 0060060

Collected: 4/17/2019 16:29 MT
Started: 4/19/2019 6:11 MT

Source: **Blood**

Body Site:

Free Text Sources:

Final Report

Culture **POSITIVE** for
Mycobacterium avium-intracellulare complex
Identification by MALDI-TOF
Test developed and characteristics determined by
ARUP Laboratories. See Compliance Statement B:
aruplab.com/CS

Susceptibility Results

Organism: Mycobacterium avium-intracellulare complex

Amikacin	Interpretation: SUSCEPTIBLE MIC (ug/mL): 8
Clarithromycin	Interpretation: SUSCEPTIBLE MIC (ug/mL): 0.5
Linezolid	Interpretation: SUSCEPTIBLE MIC (ug/mL): 8
Moxifloxacin	Interpretation: SUSCEPTIBLE MIC (ug/mL): 0.5

**S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate,
SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available**

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 19-107-137304
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 2 | Printed: 2/16/2021 7:02:56 AM
4848

Interpretive Information

Interpretation: **SEE NOTE**

For Mycobacterium avium-intracellulare complex, CLSI recommends testing and reporting clarithromycin, moxifloxacin, amikacin and linezolid. The reported amikacin interpretation is for IV; if using amikacin (liposomal, inhaled), the MIC interpretive breakpoints are <=64 ug/mL Susceptible, >=128 ug/mL Resistant. The in vivo effectiveness of Moxifloxacin and Linezolid for MAC disease is unproven. Ethambutol, rifampin and rifabutin MIC results are not reported because MIC values are not predictive of clinical responses and may be misleading.

Susceptibility performed by a non-standardized methodology. Interpret results in conjunction with clinical presentation. Test developed and characteristics determined by ARUP Laboratories. See compliance Statement B: aruplab.com/CS.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Blood Culture, Acid-Fast Bacillus (AFB)	19-107-137304	4/17/2019 4:29:00 PM	4/19/2019 1:49:39 AM	5/16/2019 8:03:57 AM

END OF CHART

S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 19-107-137304
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 2 | Printed: 2/16/2021 7:02:56 AM
4848